



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299 THAMBU CHETTY STREET, CHENNAI - 600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN:L24294 TN1995PLCO30698

To,

May 05, 2023.

Listing Department, BSE Limited, P J Towers, Dalal Street, Mumbai – 400001.	Listing Department, National Stock Exchange of India, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051.
Security Code: 532989 Security ID: BAFNAPHARM	Symbol: BAFNAPH Series: EQ.

Dear Sir/Madam,

Subject: Disclosure for Non-applicability as Large Entity.
Reference: SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144, dated November 26, 2018.

This is with regard to the SEBI Circular No. SEBI/HO/DDHS/CIR/P2018/144, dated November 26, 2018, [“SEBI Circular”] w.r.t. fund raising by issuance of Debt Securities by Large Entities, and Disclosures and compliances thereof by such Large Corporates.

We hereby confirm that “**BAFNA PHARMACEUTICALS LIMITED**” [“**the Company**”] does not fall in the category of Large Corporates as per the applicability criteria given under Para 2.2 of the aforesaid SEBI Circular as on March 31, 2023, and therefore, the requirement of filing the initial disclosure and annual disclosure in Annexure A and B1 & B2 respectively to the aforesaid Circular is not applicable.

Kindly take the same on record and acknowledge the receipt.

Thank you,

Yours faithfully,
For **Bafna Pharmaceuticals Limited**,

(Vishnu Vasudeva Kuppa)
Company Secretary & Compliance Officer.